Paper33705209
Next-Generation Endocrine Therapies for Breast Cancer.
McDonnell DP and 3 others. J Clin Oncol, 2021. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. Next-Generation Endocrine Therapies for Breast Cancer. Papers, record 33705209. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33705209
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Hormonal | Major topic |
| Breast Neoplasms | Major topic |
| Estrogen Receptor alpha | |
| Female | |
| Humans | |
| Mutation | |
| Selective Estrogen Receptor Modulators |
Source PubMed
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19875750 | Activity of fulvestrant in HER2-overexpressing advanced breast cancer. | Ann Oncol | 2010 | https://conductscience.org/library/papers/19875750 | PubMed |
| 2 | 10426998 | Peptide antagonists of the human estrogen receptor. | Science | 1999 | https://conductscience.org/library/papers/10426998 | PubMed |
| 3 | 8275477 | Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. | Cancer Res | 1994 | https://conductscience.org/library/papers/8275477 | PubMed |
| 4 | 10424402 | Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. | Breast Cancer Res Treat | 1999 | https://conductscience.org/library/papers/10424402 | PubMed |
| 5 | 10579349 | Comparative analyses of mechanistic differences among antiestrogens. | Endocrinology | 1999 | https://conductscience.org/library/papers/10579349 | PubMed |
| 6 | 24803577 | The microenvironment matters: estrogen deficiency fuels cancer bone metastases. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24803577 | PubMed |
| 7 | 33513026 | Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33513026 | PubMed |
| 8 | 15814849 | Transcriptional regulation by steroid receptor coactivator phosphorylation. | Endocr Rev | 2005 | https://conductscience.org/library/papers/15814849 | PubMed |
| 9 | 31091374 | Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31091374 | PubMed |
| 10 | 8592512 | Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. | Mol Endocrinol | 1995 | https://conductscience.org/library/papers/8592512 | PubMed |
| 11 | 29991605 | Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. | Cancer Discov | 2018 | https://conductscience.org/library/papers/29991605 | PubMed |
| 12 | 1749936 | Dopaminergic and ligand-independent activation of steroid hormone receptors. | Science | 1991 | https://conductscience.org/library/papers/1749936 | PubMed |
| 13 | 26162914 | Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. | Endocr Relat Cancer | 2015 | https://conductscience.org/library/papers/26162914 | PubMed |
| 14 | 21051656 | Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. | J Natl Cancer Inst | 2010 | https://conductscience.org/library/papers/21051656 | PubMed |
| 15 | 11306468 | Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. | Cancer Res | 2001 | https://conductscience.org/library/papers/11306468 | PubMed |
| 16 | 5767298 | Estrogen receptors in the rat uterus. Studies on the interaction of cytosol and nuclear binding sites. | J Biol Chem | 1969 | https://conductscience.org/library/papers/5767298 | PubMed |
| 17 | 9881323 | Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health. | Maturitas | 1998 | https://conductscience.org/library/papers/9881323 | PubMed |
| 18 | 6066766 | A new derivative of triphenylethylene: effect on implantation and mode of action in rats. | J Reprod Fertil | 1967 | https://conductscience.org/library/papers/6066766 | PubMed |
| 19 | 7001242 | Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. | N Engl J Med | 1981 | https://conductscience.org/library/papers/7001242 | PubMed |
| 20 | 6438654 | The pharmacology and clinical uses of tamoxifen. | Pharmacol Ther | 1984 | https://conductscience.org/library/papers/6438654 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42948694 | Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR+/HER2- advanced breast cancer. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42948694 | PubMed |
| 42072376 | Research Progress of PROTACs in Breast Cancer: Subtype-Oriented Target Landscape, Clinical Stratification Evidence, and Engineering Strategies for Translation. | Biomedicines | 2026 | https://conductscience.org/library/papers/42072376 | PubMed |
| 41999452 | Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/41999452 | PubMed |
| 41301715 | Estrogen Receptors as Key Factors in Carcinogenesis. | Biomedicines | 2025 | https://conductscience.org/library/papers/41301715 | PubMed |
| 41285747 | A ternary switch model governing ERα ligand binding domain conformation. | Nat Commun | 2025 | https://conductscience.org/library/papers/41285747 | PubMed |
| 41171336 | Research progress of DUB enzyme in breast cancer. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/41171336 | PubMed |
| 40696170 | PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2- breast cancer harbouring acquired ESR1 mutations. | Nat Rev Clin Oncol | 2025 | https://conductscience.org/library/papers/40696170 | PubMed |
| 40303343 | Sex bias in tumor immunity: insights from immune cells. | Theranostics | 2025 | https://conductscience.org/library/papers/40303343 | PubMed |
| 40103456 | Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov. | Curr Med Chem | 2025 | https://conductscience.org/library/papers/40103456 | PubMed |
| 39966355 | Breast cancer: pathogenesis and treatments. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/39966355 | PubMed |
| 39891710 | Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen? | Endocrinology | 2025 | https://conductscience.org/library/papers/39891710 | PubMed |
| 39820652 | Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/39820652 | PubMed |
| 39702552 | The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer. | NPJ Breast Cancer | 2024 | https://conductscience.org/library/papers/39702552 | PubMed |
| 39519751 | Antioxidant 1,2,3,4,6-Penta-O-galloyl-β-D-glucose Alleviating Apoptosis and Promoting Bone Formation Is Associated with Estrogen Receptors. | Molecules | 2024 | https://conductscience.org/library/papers/39519751 | PubMed |
| 39331714 | Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth. | Sci Adv | 2024 | https://conductscience.org/library/papers/39331714 | PubMed |
| 38435754 | Anti-Cancer Potency of Copper-Doped Carbon Quantum Dots Against Breast Cancer Progression. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/38435754 | PubMed |
| 38028803 | Targeting estrogen signaling and biosynthesis for aged skin repair. | Front Physiol | 2023 | https://conductscience.org/library/papers/38028803 | PubMed |
| 37684402 | Targeting sex steroid biosynthesis for breast and prostate cancer therapy. | Nat Rev Cancer | 2023 | https://conductscience.org/library/papers/37684402 | PubMed |
| 37684290 | Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. | NPJ Breast Cancer | 2023 | https://conductscience.org/library/papers/37684290 | PubMed |
| 37193881 | The G protein-coupled oestrogen receptor GPER in health and disease: an update. | Nat Rev Endocrinol | 2023 | https://conductscience.org/library/papers/37193881 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33705209
GET https://conductscience.org/api/papers/v1/33705209/references?page=2